Sensus Healthcare (NASDAQ:SRTS) Shares Cross Below 50 Day Moving Average – Here’s Why

Sensus Healthcare, Inc. (NASDAQ:SRTS)’s share price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $6.85 and traded as low as $5.36. Sensus Healthcare shares last traded at $5.38, with a volume of 280,695 shares.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on SRTS shares. Lake Street Capital initiated coverage on shares of Sensus Healthcare in a research report on Friday, January 31st. They issued a “buy” rating and a $18.00 price objective on the stock. HC Wainwright increased their price objective on Sensus Healthcare from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, February 10th. Finally, Maxim Group boosted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Price Performance

The firm’s fifty day simple moving average is $6.85 and its 200 day simple moving average is $6.84. The company has a market capitalization of $88.18 million, a PE ratio of 13.45 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. On average, equities research analysts anticipate that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its holdings in shares of Sensus Healthcare by 30.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock valued at $2,620,000 after purchasing an additional 88,953 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock worth $1,039,000 after purchasing an additional 67,269 shares during the period. Marshall Wace LLP lifted its holdings in Sensus Healthcare by 99.6% during the 4th quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock worth $915,000 after buying an additional 65,994 shares in the last quarter. Millennium Management LLC raised its stake in shares of Sensus Healthcare by 256.6% in the fourth quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock valued at $590,000 after acquiring an additional 61,403 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Sensus Healthcare in the 4th quarter valued at about $381,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.